Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study-Reference-Cited by-同舟云学术

Resistance mechanisms to osimertinib in EGFR-mutated advanced non-small-cell lung cancer: A multicentric retrospective French study

Published:2019-11 Issue: Volume:137 Page:149-156
ISSN:0169-5002
Container-title:Lung Cancer
language:en
Short-container-title:Lung Cancer

Author:

Mehlman Camille,Cadranel Jacques,Rousseau-Bussac Gaelle,Lacave Roger,Pujals Anaïs,Girard Nicolas^ORCID,Callens Céline,Gounant Valérie,Théou-Anton Nathalie,Friard Sylvie,Trédaniel Jean,Blons Hélène,Dujon Cécile,Duchemann Boris^ORCID,Schischmanoff Pierre Olivier,Chinet Thierry,Giroux Leprieur Etienne

Publisher

Elsevier BV

Subject

Cancer Research,Pulmonary and Respiratory Medicine,Oncology

Reference19 articles.

1. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French cooperative thoracic tntergroup (IFCT);Barlesi;Lancet,2016

2. AZD9291 in EGFR inhibitor–Resistant non–Small-Cell lung Cancer;Jänne;N. Engl. J. Med.,2015

3. Osimertinib or platinum–Pemetrexed in EGFR T790M–Positive lung Cancer;Mok;N. Engl. J. Med.,2017

4. Osimertinib in untreated EGFR -Mutated advanced non–small-cell lung cancer;Soria;N. Engl. J. Med.,2018

5. Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M;Thress;Nat. Med.,2015

Cited by 65 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Genome-wide CRISPR screens identify the YAP/TEAD axis as a driver of persister cells in EGFR mutant lung cancer;Communications Biology;2024-04-24

2. EGFR degraders in non‐small‐cell lung cancer: Breakthrough and unresolved issue;Chemical Biology & Drug Design;2024-04

3. Comprehensive molecular and clinical insights into non-small cell lung cancer transformation to small cell lung cancer with an illustrative case report;Journal of Drug Targeting;2024-03-25

4. Clinical Management of Patients with Non-Small Cell Lung Cancer, Brain Metastases, and Actionable Genomic Alterations: A Systematic Literature Review;Advances in Therapy;2024-03-21

5. Clinical practice guidelines for molecular tumor marker, 2nd edition review part 2;International Journal of Clinical Oncology;2024-03-17